154 related articles for article (PubMed ID: 16963731)
1. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Rojo F; Tabernero J; Albanell J; Van Cutsem E; Ohtsu A; Doi T; Koizumi W; Shirao K; Takiuchi H; Ramon y Cajal S; Baselga J
J Clin Oncol; 2006 Sep; 24(26):4309-16. PubMed ID: 16963731
[TBL] [Abstract][Full Text] [Related]
2. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
3. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Loprevite M; Tiseo M; Chiaramondia M; Capelletti M; Bozzetti C; Bortesi B; Naldi N; Nizzoli R; Dadati P; Kunkl A; Zennaro D; Lagrasta C; Campanini N; Spiritelli E; Camisa R; Grossi F; Rindi G; Franciosi V; Ardizzoni A
Clin Cancer Res; 2007 Nov; 13(21):6518-26. PubMed ID: 17975165
[TBL] [Abstract][Full Text] [Related]
4. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
Hosokawa S; Toyooka S; Fujiwara Y; Tokumo M; Soh J; Takigawa N; Hotta K; Yoshino T; Date H; Tanimoto M; Kiura K
Lung Cancer; 2009 Oct; 66(1):107-13. PubMed ID: 19185949
[TBL] [Abstract][Full Text] [Related]
7. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
Baselga J; Albanell J; Ruiz A; Lluch A; Gascón P; Guillém V; González S; Sauleda S; Marimón I; Tabernero JM; Koehler MT; Rojo F
J Clin Oncol; 2005 Aug; 23(23):5323-33. PubMed ID: 15939921
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.
Nicolle G; Daher A; Maillé P; Vermey M; Loric S; Bakkar A; Wallerand H; Vordos D; Vacherot F; de Medina SG; Abbou CC; Van der Kwast T; Thiery JP; Radvanyi F; Chopin DK
Clin Cancer Res; 2006 May; 12(9):2937-43. PubMed ID: 16675591
[TBL] [Abstract][Full Text] [Related]
9. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F; Magrini E; Ceresoli GL; Bartolini S; Rossi E; Ludovini V; Gregorc V; Ligorio C; Cancellieri A; Damiani S; Spreafico A; Paties CT; Lombardo L; Calandri C; Bellezza G; Tonato M; Crinò L
J Natl Cancer Inst; 2004 Aug; 96(15):1133-41. PubMed ID: 15292385
[TBL] [Abstract][Full Text] [Related]
10. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
11. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Cunningham MP; Thomas H; Fan Z; Modjtahedi H
Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
13. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Janmaat ML; Gallegos-Ruiz MI; Rodriguez JA; Meijer GA; Vervenne WL; Richel DJ; Van Groeningen C; Giaccone G
J Clin Oncol; 2006 Apr; 24(10):1612-9. PubMed ID: 16575012
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
16. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Ariyama H; Qin B; Baba E; Tanaka R; Mitsugi K; Harada M; Nakano S
J Cell Biochem; 2006 Mar; 97(4):724-34. PubMed ID: 16229013
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Javle M; Pande A; Iyer R; Yang G; LeVea C; Wilding G; Black J; Nava H; Nwogu C
Am J Clin Oncol; 2008 Aug; 31(4):329-34. PubMed ID: 18845990
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Cappuzzo F; Ligorio C; Jänne PA; Toschi L; Rossi E; Trisolini R; Paioli D; Holmes AJ; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Ciardiello F; Patelli M; Crino L; Varella-Garcia M
J Clin Oncol; 2007 Jun; 25(16):2248-55. PubMed ID: 17538169
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Rothenberg ML; LaFleur B; Levy DE; Washington MK; Morgan-Meadows SL; Ramanathan RK; Berlin JD; Benson AB; Coffey RJ
J Clin Oncol; 2005 Dec; 23(36):9265-74. PubMed ID: 16361624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
